Drug Discovery Group

 

Professor David C.K. Chu
Curriculum Vitae
(A Short Form)

 

 

PROFESSIONAL ADDRESS:

College of Pharmacy, University of Georgia, Athens, GA  30602-2352 
Tel: 706-542-5379  FAX: 706-542-5381  E-mail:dchu@rx.uga.edu

EDUCATION: 

Seoul National University    1964  B.S. Pharmacy 
Idaho State University         1970  M.S. Medicinal Chemistry 
State University of New York /Buffalo 1974  Ph.D. Medicinal Chemistry 
 

PROFESSIONAL AND/OR ACADEMIC POSITIONS: 

1998-present Distinguished Research Professor (University of Georgia Chaired Professor)
1998-1999 Millikan-Reeve Professor of Pharmacy (University of Georgia)-resigned to accept the above
1990-present Professor (University of Georgia)
1986-present Director, Drug Discovery Group (University of Georgia)
1987-1989 Associate Professor (University of Georgia)-tenured
1982-1986 Assistant Professor (University of Georgia)
1980-1982 Assistant Professor (Idaho State University)
1976-1980 Research Associate (Memorial Sloan-Kettering Cancer Center)
1974-1975 Postdoctoral Fellow (Memorial Sloan-Kettering Cancer Center with Drs. Fox and Watanabe)
1970-1974 Research Assistant (Suny/Buffalo)
1968-1970 Graduate Assistant (Idaho State University)
1965-1968 Navy Officer (retired as Lt. Jr. Gr.)
1964-1965 Research Assistant (Korean NIH)
 

PROFESSIONAL MEMBERSHIPS: 

 American Chemical Society (Medicinal, Organic, and Carbohydrate Division Member) 
 American Association for Cancer Research 
 American Association for the Advancement of Science 
 American Association of Colleges of Pharmacy 
 Korean American Scientists and Engineers Association in U.S. 
 The International Society for Antiviral Research 
 The Society of Biomedical Research 
 International Union of Pure and Applied Chemistry
 International Society for Nucleosides, Nucleotides and Nucleic Acids
 American Society of Microbiology
  

Top

HONORS:

NIH Advisory Committee Member  (AIDS Emphasis panel-AARR3), 1998-2002
NIH Advisory Committee Member  (Bioorganic & Natural Product Chemistry Study Section), 1995-1997
NIH Advisory Committee ad hoc member (BNP, OIG, NCDDG, SBIR), 1987-present
NIH Principal Investigator, 1986-Present
American Chemical Society (Northeast Georgia Section) Research Award, 1998
University of Georgia Creative Research Medal, 1988
Dean’s Special Award for Research Achievement, 1989
Scientific Advisory Board Member (Triangle Pharmaceuticals), 1996-present
Co-Founder & Chair, Scientific Advisory Board (Pharmasset), 1998-Present
Rho Chi Pharmacy Honor Society, 1970-present
Sigma Xi Honor Society, 1987-present
Phi Beta Delta Honor Society for International Scholars, 1989-present
Editorial Advisory Board (Nucleosides, Nucleotides & Nucleic acids), 1994-Present
President, The Society of Biomedical Research, 1995-1997
Millikan-Reeve Professor of Pharmacy (Pharmacy chaired professor), 1998-1999 (resigned to accept below)
University of Georgia Distinguished Research Professor, 1998-present
Marquis Who’s Who in the World, 2003 edition
Marquis Who’s Who in America, 2003 edition
NIH Merrit Award, 2001
Inventor of the Year Award (University of Georgia), 2002
Elected Fellow of American Association of Advancement of Science, 2002
 
 
AREA OF RESEARCH INTERESTS: 

Nucleoside and carbohydrate chemistry
Antiviral chemotherapy (HIV, hepatitis B & C virus, West Nile virus and Epstein-Barr virus)
Cancer chemotherapy
Structure-based drug design & Molecular modeling
Antiviral Drug discovery for Bioterrorism ( Smallpox, Monkeypox, Ebola, etc.)
  

Top

CURRENT RESEARCH PROJECTS:

 Drug Design and synthesis of antiviral agents for AIDS
 Drug targeting of anti-HIV nucleosides
 Drug design and synthesis of antiviral agents against small pox, West Nile, hepatitis B &  C viruses
 Synthesis of antiparasitic agents 
 Asymmetric synthesis of nucleosides from carbohydrate chiral templates 
 Molecular mechanism  and drug resitance of HIV RT
 

MAJOR ACHIEVEMENTS IN DRUG DISCOVERY 

Pseudoisocytidine for cancer (discovered 1975-Phase I-discontinued) 
AZDU (CS-87) for AIDS (discovered 1987-Phase I/II) 
AZMC (CS-92) for AIDS (discovered 1988-Phase I- discontinued) 
DAPD for AIDS/HBV (discovered 1992-Preclinical- Phase I/II) 
L-OddC for cancer (discovered 1993-Phase II clinical trials)
L-FMAU for HBV (discovered 1993-Phase I/II trials) 
L-IOddU for EBV (discovered 1996-Preclinical)
DOT for HIV (discovered 2000-Preclinical) 

    

Top

   

The following is a selected list of publications in peer reviewed journals from our group.
For a reprint of a publication, please contact Professor Chu.

RECENT PUBLICATIONS - (2000-Present)

200. Chu, C.K.; Ma, L.; Olgen, S.; Pierra, C.; Du, J.; Gumina, G.; Gullen, E.; Cheng, Y.-C.; Schinazi, R.F. Synthesis and Antiviral Activity of Oxaselenolane Nucleosides. J. Med. Chem., 2000, 43, 3906-3912.

 

201. Li, L.; Dutschman, G.; Gullen, E.; Tsujii, E.; Grill, S.; Choi, Y.S.; Chu, C.K.; Cheng, Y.-C. Metabolism and Mode of Inhibition of Varicella-Zoster Virus by L-b-5-Bromovinyl-(2-hydroxymethyl)-1,3-dioxolanyl)uracil Is Dependent on Viral Thymidine Kinase. Mol. Pharmacol., 2000, 58, 1109-1114.

 

202. Kira, T.; Grill, S.P.; Dutschman, G.E.; Lin, J.-S.; Qu, F.; Choi, Y.S.; Chu, C.K.; Cheng, Y.-C. Anti-Epstein-Barr Virus (EBV) Activity of L-5-Iododioxolane Uracil Is Dependent on EBV Thymidine Kinase. Antimicrobial Agents & Chemother., 2000, 44(12), 3278-3284.

 

203. Chong, Y.; Gumina, G.; Chu, C.K. Divergent Synthesis of D- and L- Carbocyclic 4’-Fluoro-2’,3’-Dideoxynucleosides As Potential Antiviral Agents. Tetrahedron: Asymetry, 2000,11 (24), 4853-4875.

 

204. Furman, P.A.; Jeffrey, J.; Kiefer, L.L.; Feng, J.; Anderson, K.S.; Borrota-Esoda, K.; Hill, E.; Copeland, W.C.; Chu, C.K.; Sommadossi, J.P.; Liberman, I.; Schinazi, R.F.;  Painter, G.R. Mechanism of Action of 1--D-2, 6-Diaminopurine Dioxolane: A Prodrug of the HIV-1 Inhibitor 1--D-Dioxolane Guanosine. Antimicrobial Agents & Chemother., 2001, 45(1), 158-165.

 

205. Lee, K.; Chu, C.K. Understanding the Mode of Action of L-Nucleosides as Antiviral Agents: A Molecular Modeling Approach. Antimicrob. Agents Chemother., 2001, 45(1), 138-144.

 

206. Cho, S.; Kim, Y.; Cruz, M.O.; Park, E.-M.; Chu, C.K.; Lee, K.; Joh, T. H. Repression of proinflammatory cytokine gene expression in activated microglia by N-acetyl-O-methyldopamine: Protein kinase A-dependent mechanism. Glia,   2001, 33, 324-333.

 

207. Chun, B.K.; Song, G.Y.; Chu, C.K. Stereocontrolled Syntheses of Carbocyclic C-Nucleosides and Related Compounds. J. Org. Chem., 2001, 66, 4852-4858.

 

208. Gumina, G.; Song, G.Y.; Chu, C.K. Advances in Antiviral Agents for Hepatitis B Virus.  Antiviral Chem. Chemother., 2001, 12, 89-112.

 

209. Korba, B.E.; Cote, P.; Baldwin, B.H.; Wells, F.V.; Peek, S.F.; Hornbuckle, W.E.; Toshkov, I.A.; Chu, C.K.; Gerin, J.L.; Tennant, CB.C.; Jacob, J.R. Antiviral Activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, 1-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax). Hepatology, 2001, 33, 254-266.

 

210. Choo, H.; Chong, Y.H.; Chu, C.K. Solid Phase Synthesis of Carbocyclic L-2’-Deoxynucleosides, Organic Letters, 2001, 3, 1471-1473.

 

211. Clark, T.N.; White, C.A.; Chu, C.K.; Bartlett, M.G. Determination of 3’-Azido-2’-3’-Dideoxyridine (AZDU) in maternal Plasma, Amniotic Fluid, Fetal and Placental Tissues by High Performance Liquid Chromatography, J. Of Chromatography B, 2001, 755,165-172.

 

212. Gumina, G.; Song, G.Y.; Chu, C.K. L-Nucleosides as chemotherapeutic agents-mini review, FEMS Microbiology Letters, 2001, 202, 9-15.

 

213. Gumina, G.; Schinazi, R.F.; and Chu, C.K. Synthesis and potent anti-HIV activity of L-3’-fluoro unsaturated cytidine, Organic Letters, 2001, 3, 4177-4180.

 

214. Song, G.Y.; Paul, V.; Choo, H.; Morrey, J.; Sidwell, R.W.; Schinazi, R. F.; and Chu, C.K. Enantiomeric Synthesis of D- and L-Cyclopentenyl Nucleosides and their Antiviral Activity Against HIV and West Nile Virus, J. Med. Chem., 2001, 44,  3985-3993.

 

215.Song, G.Y.; Naguib, F.N.M.; el Kouni, M.;, Chu, C. K. Synthesis of carbocyclic analogs as potential orotidine decarboxylase inhibitors, Nucleosides, Nucleotides & Nucleic Acids, 2002, 20, 1915-1925.

 

216. Lee, K.; Choi, Y.S.; Gumina, G.; Zhou, W.; Schinazi, R.F.; and Chu, C.K. Structure-Activity Relationships of 2’-Fluoro-2’,3’-unsaturated D-Nucleosides as Anti-HIV-1 Agents. J. Med. Chem., 2002, 45, 1313-1320.

 

217. Chong, Y.H.; Chu, C.K. Efficient synthesis of 2-deoxy-L-erythro-pentose (2-deoxy-L-ribose) from L-arabinose. Carbohydrate Research, 2002, 332, 397-402.

 

218. Choi, Y.S.; Choo, H.; Chong, Y. Lee, S.; Olgen, S.; Schinazi, R.F.; and Chu, C.K. Synthesis and Potent Anti-HIV Activity of L-2’,3’-Didehydro-2’,3’-dideoxy-2’-fluoro-4’-thiocytidine. Organic Letters, 2002, 4, 305-307.

 

219. Ray, A.S.; Yang, Z.; Chu, C.K. and Anderson, K.S. A Novel Use of a guanosine prodrug Approach to convert D4G into a viable Antiviral Agent., Antimicrobial Agents and Chemother., 2002, 46,887-891.

 

220.  Cooperwood, J.S.; Gumina, G.; Vorobiev, A.; Boudinot,F.D.; Chu, C.K. Nucleoside Prodrugs- Recent Advances in Nucleoside: Chemistry and 

        Chemotherapy, C.K. Chu Ed., 2002, Elsevier.

 

221.  Gumina, G.; Chu, C. K. Synthesis of L-Oxetanocin, Organic Letters, 2002, 4, 1147-1149.

 

222.  Jin, Y.H.; Chu, C. K. Efficient and practical synthesis of D-cyclopent-3-enone, the intermediate for the synthesis of carbocyclic nucleosides, Tet.Letts., 2002, 43, 4141-4143.

 

223.  Ray, A.S.; Yang, Z.J.; Shi, J.; Hobbs, a.; Schinazi, R. f.; Chu, C. K.; Anderson, K.S. Insight into the molecular mechanism of inhibition and drug resistance of HIV-1 RT with 

        carbovir triphosphate, Biochemistry, 2002, 41, 5150-5162.

 

224.  Gumina, G.; Chong, Y.H.; Choo, H.; Song, G.Y.; Chu, C. K. L-Nucleosides: antiviral and molecular mechanism, Current topics in Med. Chem. 2002,  Current Topics in Med. 

       Chem. 2002, 2, 1065-1086.

 

225.  Lee, K.; Zhou, W.; Kelley, L.C.; Momany, C.; Chu, C.K. Synthesis of Vinyl fluoride containing D- and L-pyranosyl nucleosides from D-glyceraldehyde, Tetrahedron 

       Asymmetry, 2002, 13, 1589-1598.

 

221.  Chong, Y. H.; Chu, C. K. Understanding the unique mechanism of L-FMAU (clevudine) against heparitis B virus: molecular dynamics studies, Bioorg. Chem. Med. Chem. Letts. 2002, 12,3459-3462.

 

222.  Chong, Y.; Borroto-Esoda, K.; Furman, P.A.; Schinazi, R.F.; and Chu, C.K. Molecular mechanisms of DAPD/DXG against zidovudine- and lamivudine- drug resistance drug resitant mutant: A molecular modeling approach, Antimicrob. Chemistry Chemother., 2002, 13, 115-128.

 

223.  Stuyver, L.J.; Lostia, S.; Adams, M.; Mathew, J.S.; Pai, B. S.; grier, J.P.; Tarnish, P.M.; Choi, Y.S.; Chong, Y.H.; Choo, H. Chu, c.K.; Otto, M.J.; Schinazi, R.F. Antiviral activity and cellular toxicity of 2’,3’-dideoxy-2’,3’-didehydrocytidine  analogs,  Antimicrob. Agents. Chemother. 2002, 46, 3854-3860.

 

229. Chu, C.K.; Jin, Y.H.; Baker, R.O.; Huggins,J. Antiviral Activity of Cyclopentenyl nucleosides against Orthopox viruses (Smallpox, Monkeypox and Cowpox), Bioorganic & Med. Chem. Letts, 2002  13, 9-11.

230.  Chong, Y.H.; Choo, H.A.; Choi, Y.S.; Schinazi, R.F.; Chu, C.K.Stereosynthesis and antiviral activity of D-2’,3’-didehydro-2’,3’-2’-fluoro-4’-thionucleosides, J. Med. Chem., 2002,  45, 4888-4898.

       

231. Stuyver, L.J.; Whitaker, McBrayer, T.R.; Hrtnandez, B.I.; Lostia, S. ; Tarnish, P.M. Ramesh, M.; Chu, C. K.; Shi, J.; Jordan, R.; Watnabe, K.A.; Rachakonda, S.; Otto, M.J.; Schnazi, A ribonucleoside analogue that selectively blocks the replication of bovine viral diarrhea and hepatitis C viruses in culture, Antimicrob. Agents. Chemother., 2003, 47, 244-254.

       

232. Choo, H.A.; Chong, Y.H.; Choi, Y.S.; Mathew, J.; Schinazi, R.F; Chu, C. K. Synthesis, anti-HIV activity and molecular mechanism of drug resistance of L-2’,3’-didehydro-2,3’-dideoxy-2’-fluoro-4’-thionucleosides, J. Med. Chem. , 2003, 46, 389-398.

 

233. Chen, H.; Pai, B.; Hurwitz, S.J.; Chu, C.K.; Glazkova, Y.; MaClure, H.M.; Feitelstein, M.; Schinazi, R. F. Antiviral activity and pharmacokinetics of 1-(2,3-dideoxy-2-fluoro--L-glyceropent-2-enofuranosyl)cytosine, Antimicrob. Agents Chemother., 2003, 47, 1922-1928.

 

234. Choo, H.A.; Chong, Y.H.; Chu, C.K. The Role of 2’,3’-unsaturation  against 3TC resitance mutant in HIV reverse transcriptase, Bioorganic & Med. Chem. Letts., 2003,13, 1993-1996.

 

235. Chong, Y.H.; Gumina, G.; Mathew, J.; Schinazi, R.F.; Chu, C.K. L-2’, 3’-Dihydro-2’,3’-dideoxy-3’-fluoronucleosides: Synthesis, anti-HIV activity, chemical and enzymatic stability amd the mechanism of resistance, J. Med. Chem. 2003, 46, 3245-3256.

 

236.   Zhu, W.; Gumina, G.; Schinazi, R.F.; Chu, C. K. Synthesis and anti-HIV activity of L-3’-C-cyano 2’, 3’-unsaturated nucleosides and L-3’-C-cyano-3’-deoxyribonucleosides, Tetrahedron, 2003, 59, 6423-6431.

 

237.  Jin, Y.H.; Liu, P.; Chu, C.K. Practical synthesis of D- & L-cyclopent-2-3none and and their utility for the synthesis of carbocyclic antiviral nucleosides against orthopox viruses (smallpox, Monkeypox and cowpoxvirus), J. Org. Chem. 2003, 68, 9012-9018.

 

238.  Chong, Y.H.; Akula, N.; Chu, C.K. Studies of molecular mechanism of tenofovir against 3TC- and AZT-resistance mutant HIV-1 reverse transcriptase, Bioorg. Med. Chem. Letts. 2003, 13, 4019-4022.

 

239.  Ray, A.S.; Schinazi, R.F. Murakami, E.; Basavpthruni, A.; Shi, J.; Zorea, S.; Schinazi, R.F.; Chu, C. K.; Anderson,  Probing the mechanistic consequences of 5-fluoro substitution on cytidine nucleotide analogs incorporation by HIV-1 reverse transcriptase, Antiviral chem. Chemother, 2003, 14, 115-125.

 

240.  Kong, L.; cooperwood, J,; Huang, C.; Chu, C.K.; Boudinot, F.D. Pharmacokinetic evaluation of 3'-azido-2', 3'-dideoxyuridine-5'-O-valinate-hydrochloride as a prodrug of the anti-HIV nucleoside 3'-azido-2', 3'-dideoxyuridine, Antimicrob. Chem. Chemother. 2003, 14, 263-270.

 

241.  Kong, Linghui, Cooperwood, John S., Oh, Chang H., Chu, Chung K., and Boudinot, F. Douglas. Simultaneous determination of 3’-azido-2’,3’-dideoxyuridine and novel prodrugs in rat plasma by liquid chromatography.  Journal of Chromatography B, 2003, 795, 371-376.

 

242.  Stuyver, L.; McBrayer, T.R.; Tharnish, P.M.; Hassan, A. E.A.; Chu, C.K.; Pankiewicz, K.W.; Watanabe,  K.A.; Schinazi, R.F.; Otto, M.J. Dynamics of subgenomic HCV replicon RNA levels in Huh7 cells after exposure to nucleoside antimetabolites, J. Virology, 2003, 77, 10689-10694.

 

243.  Chong, Y.H.; Chu, C. K. Understanding the molecular mechanism of drug resistance of anti-HIV nucleosides by molecular modeling, Frontiers in Bioscience, 2004, 9, 164-186.

 

244.  Chong, Y.H.; Choo, H.A.; Chu, C.K. Effects of fluorine substitution of cytosine analogs on the binding affinity to HIV-1 reserse transcriptase, Bioorg. Med. Chem. Letts. 2004, 14, 437-440.

 

245.  Park, E.M.; Joh, T.H.; Volpe, B.T.; Chu, C.K.; Song, G.; Cho, S. A neoroprotective role of extracellular signal-regulated kinase in N-acethyl-O-methyldopamine-treated hippocampal neurons after exposure to in vitro and in vivo ischemia, Neuroscience, 2004, 123, 147-154.

 

246.  Song, J. Wang, X.-L.; Xiang, Y.-J.; Chu, C. K.; Schinazi, R.; Zhao, K.Synthesis of É¿-L-2',3'-Dideoxy-2'-fluoro-3'-hydroxymethylarabinofuranosyl Pyrimidine Nucleosides, Chinese Chem. Lett, 2004, 15, 135-7.

 

247.  Zhu, W.; Chong, Y.H.; Choo, H.; Chong, Y.H. Mathews, J.; Schinazi, R.F.; Chu, C. K. Synthesis, structure-activity relationships, mechanism of drug resistance of D-and  L--3’-fluoro-2’,3’-didehydro-2’,3’-dideoxy-4’-thionucleosides, J. Med. Chem.  2004, 47, 1631-1640.

 

248.  Shi, J.X.; Ray, A.S.; Mathew, J.S.; Anderson, K.S.; Chu, C.K.; Schinazi, R.F. 2’,3’-Didehydro-2’,3’-dideoxy   are degraded to furfuryl alcohol under acidic conditions, Bioorg. Med. Chem. Letts, 2004, 14, 2159-2162.

 

249.  Chong, Y.H.; Chu, C.K. Molecular mechanism of dioxolane nucleosides against 3TC resistant HIVM184 mutant, Antiviral Research. 2004, 63, 7-13.

 

250.  Yadav, V.; Rais, R.; Naguib, F.N.M.; el Kouni, M.; Chu, C.K. Design, synthesis, molecular modeling and focused combinatorial library for lead optimization of benzylthioinosine analogs as subversive substrates of T. gondii adenosine kinase, J. Med. Chem. 2004, 47, 1987-1996.

 

251.  Hollecker, L.; Lostia, S.; McBrayer, T.R.; Chu, C. K. Stuyver, L.J.; Rachakonda, S.; Shi, J.; Watanabe, K. A. Synthesis of -D- and -L-3’- deoxypyrimidines and their antiviral evaluation on bovine viral diarrhea virus and hepatitis C virus in cell culture, Antiviral Chem. Chemother. 2004, 15, 43-55.

252.  Zhou, W.; Gumina, G.; Chong, Y.H.; Wang, J.; Schinazi, R.F.; Chu, C.K. Synthesis, structure-activity relationships and drug resistance of D-3’-fluoro-2’,3’ -unsaturated nucleosides as anti-HIV agents, J. Med. Chem. 2004, 47, 3399-3408.

       

253. Bondada, L.; Gumina, G.; Nair, R.; Ning, X.H.; Chu, C. K. Synthesis of novel spiro [2.3] hexane carbocyclic   nucleosides via enzymatic resolution, Organic Letts. 2004, Organic Lettrs. 2004, 6, 2531-2534.

 

254.     Yadav, v.; Chu, C.K. Molecular mechanism of Adeforvir sensitivity and resistance in HBV polymerase mutants: A molecular dynamic study, Bioorg. Med. Chem. Letts, Bioorg. Med. Chem. Letts, 2004, 14, 4313-4317.

 

255.     Hernandez-Santiago, B.I.; Beltran, T.; Stuyver, L.; Chu, C. K.; Schinazi, R.F. Metabolism of the anti-hepatitis C virus nucleoside -D-N4-hydroxycytidine in different liver cells, antimicrob. Agents. Chemother. 48, 4636-4642.

 

256.     Choo, H.A. Chong, Y.H.; Gumina, G.; Chu, C. K. Advances in antiviral nucleosides in Frontiers in Nucleosides and Nucleic Acid, Schinazi and Liotta (Edition), IHL Press, 2004, in press.

 

257.     Wang, P.Y.; Adams, M.; Grier, J.P.;Pai, B.; Mathew, J.; Watanabe, K.A.; Otto, M. J.; Gumina, G.; Chu, C.K.; Schinazi, R.F. Synthesis and in vitro anti-HIV activity of 2’-fluoro-2’,3’-didehydro-2’,3’-dideoxypurine nucleosides in Frontiers in Nucleosides and Nucleic Acid, Schinazi and Liotta (Edition), IHL Press, 2004, in press.

 

258.    Chong, Y.H.; Chu, C.K. Mechanism of antiviral activities of 3’-substituted L-nucleosides against 3TC-resistant HBV polymerase, Antiviral Chem. Chemother. 2004, in press.

 

259.     Gumina, G.; Chu, C. K. L-Nucleosides as chemotherapeutic agents, Book chapter, 2004, in press.

 

260.     Chen, X.; Zhou, W.; Schinazi, R.F.; Chu, C.K. Synthesis of 3’-fluoro-2’,3’-unsaturated-4’-ethynyl D- & L-furanosyl-nucleosides, J. Org. Chem. 2004, in press.

 

 

Top

PATENTS:

 

1.         U.S. Patent #4074042 - 1978

            “Pseudo-Isocytidine” 

2.         U.S. Patent #41 71429 - 1979

            “Pyrimidine to Pyrimidine Transformation Process” 

3.         U.S. Patent #4681933 - 1987

            “2’,3’-Dideoxy-5-Substituted Uridines and Related Compounds as Antiviral  Agents”    

4.         U.S. Patent #4751221 - 1988

            “2-Fluoro-arabinofuranosyl purine nucleosides”

5.         U.S. Patent #4841 039 - 1989

            “2’,3-dideoxy-5-substituted uridines and related compounds as antiviral  agents”

6.         U.S. Patent #4916122 - 1990

            “3’-azido-2’,3’-dideoxyuridine anti-retroviral composition” 

7.         U.S. Patent #4918179 - 1990 

            “2-Fluoro-arabinofuranosyl purine nucleosides”

8.         U.S. Patent #4987224 - 1991

            “Method of preparation of 2’,3’-dideoxynucleosides” 

9.         U.S. Patent #5068 320 -1991

            “2-Amino-6-(Cyclopropylamino)Purine-9-ß-D-2’,3’-Dideoxyribofuranoside and its Pharmaceutically Acceptable Salts” 

10.       U.S. Patent #5077279 - 1991

            “3’-Azido-2’,3’-Dideoxy-5-Methylcytidine Anti-Viral Composition” 

11.       U.S. Patent #5118672 -1992

            “5’-Diphosphohexose Nucleoside Pharmaceutical Compositions” 

12.       U.S. Patent #5084445 -1992

            “3’-Azido-2’,3’-Dideoxy-5-Methylcytidine” 

13.       U.S. Patent #5159067 - 1992

            “5’-Diphosphohexose Nucleoside Pharmaceutical Compositions” 

14.       U.S. Patent #5175267 - 1992

            “Stereoselective Glycosylation of Heterocyclic Bases”

15.       U.S. Patent #5179104 - 1993

            “Process for the Preparation of Enantiomerically  Pure ß-D-(-)-Dioxolane-        Nucleosides”

16.       Japanese Patent #1416343 -1988

17.       U.S. Patent #5238947-1993

            “Synthetic Piperidinediones with Cytostatic Activity”

18.       U.S. Patent #5200514-1993

            “Synthesis of 2’-Deoxypyrimidine Nucleosides”

19.       U.S. Patent #5190926-1993

            “3’-Azido-2’,3’-Dideoxypyrimidines and Related Compounds as Antiviral Agents” 

20.       U.S. Patent #5248776-1993

            “Process for Enantiomerically Pure ß-L-1,3-     Oxathiolane Nucleosides”

21.       U.S. Patent #5384396 -1995

            “Process for the Deoxygenation of Nucleosides”

22.       U.S. Patent #5455339 -1995

            “Method for the Preparation of 2’,3’-Dideoxy and 2’, 3’-Dideoxydide-Hydro Nucleosides”

23.       U.S. Patent #5565438 - 1996

            “L-Nucleosides for the Treatment of Epstein-Barr Virus”

24.       U.S. Patent #5567688 - 1996

            “L-Nucleosides for the Treatment of Hepaptitis B-Virus”

25.       U.S. Patent #5648489 - 1997

            “Improved Synthesis of Acyclic Guanine Nucleosides”

26.       U.S. Patent #5,767,122 - 1998

            “Enantiomerically Pure -D-Dioxolane Nucleosides”

27.       U.S. Patent #5,792,773 - 1998

            “L--Dioxolane Uridine Analog Administration for Treating Epstein-Barr Virus Infection”

28.       U.S. Patent # 5,817,667 - 1998

            “Compounds and Methods for the Treatment of Cancer

29.       U.S. Patent # 5,753,789 - 1998

            “Oligonucleotides Containing L-Nucleosides”

30.       U.S. Patent # 5,925,643 - 1999

            “Enantiomerically Pure -D-Dioxolane Nucleosides”

31.       U.S. Patent # 6,022,876 - 2000

“L--Dioxolane Uridine Analogs and Methods for Treating and Preventing Epstein-Barr Virus Infections”

32.       U.S. Patent # 6,063,787 - 2000

            “Methods for the Treatment of Psoriasis and Genital Warts”

33.      U.S. Patent # 6,197,777 – 2001

“Synthesis, Anti-Human Immunodeficiency Virus and Anti-Hepatitis B Virus of 1,3-Oxaselenolane Nucleosides”

34.              U.S. Patent #6,274,589 – 2001

“L-b-Dioxolane Uridine Analogs and their Pharmaceutical Compositions”

35.              U.S. Patent #6,271,212 – 2001

“Prodrugs Azide Compositions and Compounds”

36.              U.S. Patent #5808,040-2002

“ L-Nucleosides Incorporated into Polymeric structures for Stabilization of Oligonucleotides”

37.              U.S. Patent #6,348,587-2002

“2’-Fluoronucleosides”

38.              U.S. Patent #6,436,948 B1-2002

“ Method for the Treatment of Psorisis and Genital Warts”

39.       U.S. patent #6,590,107 B1-2003

“Synthesis, Anti-human Immunodeficiency Virus and Anti-hepatitis B Virus Activities of 1,3-Oxathiolane Nucleosides”

40.              U.S. patent #6,512,107 B2 –Jan. 28, 2003

“Process for the Preparation of 2’-Fluoro-5-methyl--L-arabinofuranosyluridine”

41.              U.S. patent #6,653,318 B1-Nov. 25, 2003

“5-(E)-Boromovinyl uracil analogues and related pyrimidine nucleosides as antiviral agents and methods of use”

42.              U.S. patent #6,670,342 B2-Dec. 30, 2003

“Method of treating hepatitis delta virus infection”

  

Top

BOOKS (Edited) 

1.  Natural Product as Antiviral Agents (Chu & Cutler)-1992. 
2.  Nucleosides as Antiviral and Anticancer Agents (Chu & Baker)-1993. 
3.  Recent Advances in Nucleosides: Chemistry and Chemotherapy (Chu)-2002
4.  Antiviral Nucleosides:Chiral synthesis and Chemotherapy (Chu Edition)-2003

SYMPOSIUM (Organized)

  1. Korean-American AIDS Symposium, Seoul, Korea, June 14-15, 1990. 
  2. American Chemical Society (Agricultural & Food Chemistry Division), New York, N.Y.,  August, 1991 (co-organizer). 
  3. American Chemical Society (Carbohydrate Division), Spring, San Francisco, CA,April 7, 1992, (co-organizer). 
  4. 5th International Symposium on Antiviral Agents, Seoul, Korea, June 21 -25, 1992 (co-chairman). 
  5. 6th International Symposium on Antiviral Agents, Nice, France, June 7 - 10, 1994 (International Scientific Advisory Board) 
  6. International Conference on Therapies for Viral Hepatitis, Honolulu, Hawaii, Dec. 16-22, 1995 (International Scientific Advisor) 
  7. International Society for Antiviral Research, 1997 (Local organizing committee).
  8. 7th International Antiviral Symposium, Sydney, Australia, Feb. 15-19, 1997 (International Scientific Advisor). 
  9. Satellite Symposium of International Society for Antiviral Research, Emory University, April 5-6, 1997, Atlanta, GA (Co-Chair) 
10. 2nd International Conference on Therapies for Viral Hepatitis, Kona, Hawaii, Dec. 15-19, 1997 (International Scientific Advisor). 
11. The Jack Fox Symposium, San Francisco, CA, September 10, 2000 (Chair)
12. Frontiers in Drug Development for Viral hepatitis, Maui, Hawaii, Dec. 16-20, 2001 (Scientific Committee).
13. 1st International Meeting on Medicinal and Pharmaceutical Chemistry, Ankara, Turkey, September 25-28, 2002 (Scientific
      Advisory Committee).
 

NATIONAL/INTERNATIONAL MEETING CHAIR

 1.  American Chemical Society Carbohydrate Division, New York National Meeting, 1990. 
 2.  American Chemical Society Carbohydrate Division, Washington, D.C. National Meeting, September, 1990. 
 3.  American Chemical Society Carbohydrate Division, Atlanta National Meeting, April, 1991. 
 4.  American Chemical Society Nucleoside Symposium, San Francisco, CA, April, 1992. 
 5.  5th Intemational Symposium on Antiviral Agents, Seoul, Korea, June, 1992. 
 6.  American Chemical Society Carbohydrate Division, Washington, D.C., August, 1992. 
 7.  American Chemical Society Carbohydrate Division, Denver, CO., March, 1993. 
 8.  American Chemical Society Carbohydrate Division, Chicago, IL, August, 1993. 
 9.  International Symposium on Recent Advances in Chemotherapeutic Agents, Seoul, Korea, August, 1993. 
10. American Chemical Society Carbohydrate Division, San Diego, CA., March, 1994. 
11. 10th International Conference on Antiviral Research: Satellite Symposium, Atlanta, GA, April,1997.
12. Eighth International Antiviral Symposium and Workshop, Nov. 19-21, 2000, Kagoshima, JAPAN.
13. XIV International Roundtable, September 10-14, 2000, San Francisco, CA.
14. 10th International Symposium on Purines and Pyrimidines in Man: Basic and Clinical Aspects,May14-19, 2000, Tel Aviv, ISRAEL.
15. 13th International Conference on Antiviral Research, April 16-21, 2000, Baltimore, MD. 
16. 14th International Conference on Antiviral Research, April 16-21, 2000, Baltimore, MD. 
17. Frontiers in Drug Development for Viral Hepatitis, December 16-20, 2001, Maui, Hawai

 

 

 

 

Comments, Suggestions, Questions or Requests for Reprints

 

yadavv@rx.uga.edu

 

Last Update: 12/01/04